Search

Amuvatinib

Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3.

Enlicitide

Enlicitide is a macrocyclic peptide inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9). … It is formulated as enlicitide decanoate alongside the permeation enhancer sodium caprate, which facilitates absorption of the peptide across the gastrointestinal tract, though oral bioavailability remains

Palbociclib

It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male

Dolutegravir

[A7514] The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity.

Camphor

It is used topically as a skin antipruritic and as an anti-infective agent. … It appears in the list of drug products withdrawn or removed from the market for safety or effectiveness.

Pirfenidone

[A251370] It is an antifibrotic agent with anti-inflammatory and antioxidant properties [A251370] that is used to treat idiopathic pulmonary fibrosis (IPF),[L26801] which is a chronic, progressive form

Equine Botulinum Neurotoxin E Immune FAB2

It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes E in adults and pediatric patients.

Equine Botulinum Neurotoxin C Immune FAB2

It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes C in adults and pediatric patients.

Chlorphenesin

Protein S human

It serves as a negative feedback mechanism in the coagulation cascade.